Please assess the completion status of the following clinical trial:

Trial Title: A PET Imaging Agent to Assess the Level of Tumor Tissue-infiltrating CD8 + T Cells in Patients With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-70 years (including boundary values);~2. Have behavioral ability, and voluntarily participate in this clinical study, and sign the informed consent form (ICF);~3. Performance status (ECOG) score 0-1 points (see Appendix 1 for details);~4. Basal heart rate 60-100 beats/min (including boundary values);~5. Blood pressure measurement \< hypertension grade 1 level (including a history of hypertension, systolic blood pressure \< 140 and diastolic blood pressure \< 90 mmHg by exercise or drug treatment);~6. Patients with confirmed solid tumors;~7. Patients who must have at least one image-measurable lesion according to the evaluation criteria for solid tumors (RECISTv1.1);~8. Imaging results show that at least one tumor lesion can be needle biopsy or surgical treatment to obtain specimens (enhanced CT, enhanced MRI or 18F-FDG PET/CT results are acceptable);~9. Patients with immunohistochemical CD8 results within the past month;~Exclusion Criteria:~1. Those who are unable to follow this clinical trial protocol well enough to make visits, or undergo relevant examinations, or treatment.~2. Those who have extremely poor nutritional status and cannot tolerate the trial~3. Those with comorbid major diseases or other malignancies (except those that have healed by one year or do not require additional treatment)~4. Those with known severe allergy to SNA006, similar drugs or excipients. Specialized conditions~5. Patients who have undergone previous splenectomy or splenic disease such as hypersplenism or splenomegaly~6. Patients with brain metastases.~7. Serum virology tests: positive results for any of hepatitis B virus surface antigen, hepatitis C virus antibodies, syphilis-specific antibodies or those who cannot be determined to be negative for human immunodeficiency virus antibodies~8. Patients who have not recovered from a serious infection~9. Patients with drug/alcohol abuse, severe mental disorders~10. Those with claustrophobia, emotional instability, acute persistent spasticity or inability to keep both arms up and lying flat for 15-30 minutes~11. Those who have participated in any other clinical trial within 3 months prior to screening~12. Women who are pregnant or breastfeeding.~13. Those who, in the opinion of the investigator, are not suitable to participate in this clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 68Ga-NODAGA-SNA006 (Type: EXPERIMENTAL): A PET contrast agent to assess the level of tumor tissue-infiltrating CD8 + T cells in patients with solid tumors

Based on this trial design, predict the completion outcome and termination type (if applicable).